We are a core of dedicated partners and consultants, having accrued together hundreds of years of experience and expertise in the healthcare industry
Our team includes physicians, pharmacists, science PhDs and health economists. All team members have been working within the field of market access for many years and hold a track record at pharmaceutical/medical device companies, within healthcare authorities, and as practising healthcare providers.
Through our extensive network, we work with leading experts to build bridges over gaps.
- Providing access goes through communicating value to payers and other key stakeholders who will decide about priorities
- All our expertise and efforts are geared towards providing patients access to the optimal treatment fort heir illness.
- Value is both therapeutic and economic and rests on complex datasets
MEET THE TEAM
Marc Czarka, MD – General Manager
Dr. Marc Czarka, specialist in pharmaceutical medicine, has more than 20 years’ experience in three of the top 15 pharmaceutical companies, in local as well as European assignments. His experience includes medical and pharmaceutical affairs, market access as well as business development, governmental affairs, communication, and crisis management.
Dr. Czarka was general manager of several consultancies from 2005 onwards before joining Vivactis in 2018 to become the global general manager of the market access business unit (Vivactis-HM3A)
In addition, Dr. Czarka was a visiting faculty member at INSEAD, the world renowned business school, where he received executive education. Dr. Czarka taught innovation and R&D in the pharmaceutical industry to MBA students. He was also a scientific contributor at ULB (Free University Brussels) within the department of Health Economics at the School of Public Health and still teaches market access and health economics in several post graduate programs at ULB.
Barbara D’haene, PhD – COO
Barbara holds a PhD in Biomedical Sciences (Ghent University, Belgium) and received training in Conceptual Selling (Miller Heiman) and Digital Transformation (Vlerick Business School, Belgium). In 2020, Barbara was nominated as one of the 50 most inspiring women in Belgian Tech.
She acquired Sales and Marketing, Business Development and Management skills in an international context within companies providing life science services. She was the co-founder and CEO of the healthtech company Akcelis that developed and commercialized tools and services for digital patient recruitment in clinical trials. As a pioneer within Europe, Akcelis became a trusted partner of top 5 pharma and biotech companies managing large international projects across Europe. In 2020, this scale-up was acquired by the Pivotal, a full-services contract research organization for the healthcare industry across Europe. For two years, Barbara was Director Patient Journey at Pivotal before continuing her career as an independent consultant. In May 2022, she joined Vivactis HM3A.
Christian Huyghe, MD – Partner
Dr. Christian Huyghe studied medicine at the University of Ghent and graduated in 1980. He then went to the Netherlands to specialize in internal medicine and oncology. He joined the pharmaceutical industry in 1985, where he held several positions in major pharmaceutical companies, of which the most important ones were in market access and medical affairs. Since 2009, he joined Vivactis HM3A together with three other partners, specialized in market access in the EU markets for Biopharmaceuticals and Medical Devices
JACQUES GOLDSTEIN, MD – MEDICAL DIRECTOR
Jacques Goldstein is a cardiac surgeon (MD, PhD) with more than thirty years of experience in academic hospitals, with extensive experience in pacemaker and defibrillator implantation. Jacques has a broad experience in supporting the implementation of new clinical technologies and medical devices (educational programs, supervision of preclinical and clinical studies, implementation and compliance of new medical regulations). In this role he has worked with Baxter (Medical Director Global Acute Therapies), Edwards Lifesciences (Director Clinical Outcome EMEA), Medtronic and St. Jude Medical, among others.
After a research fellowship on myocardial protection at Duke University Medical Center (Durham, NC, USA), he has taught Cardiac surgery at the Université Libre de Bruxelles and at the Vrije Universiteit Brussel. He is author of more than sixty scientific publications.
Sacha Masson, PharmD – Market Access Consultant
Sacha is an Industrial Pharmacist, and graduated from Leuven as a Master in Drug Development in 2019. She followed an Interdisciplinary Program in Healthcare Innovation and received training on Skill Development in Applied Marketing Track and Communication Track (AFC Leuven). After her studies, she immediately started as an independent consultant, developing skills in Quality Assurance, Pharmacovigilance or Regulatory Affairs through the Benelux and already working and acquiring experiences in Market Access through the Vivatis HM3A-activities. In 2021, Sacha obtained the agreement from the authorities as a recognized and authorized Responsible Person for Information and Publicity. Since 2021, co-founder and CEO of the company “KSPS”, a consultancy bureau specialized in the healthcare industry across Benelux and committed to deliver value and quality through objective and eﬀective advice on Quality Assurances, Regulatory Affairs, Publicity and Compliance or Vigilance, for medicinal products and medical devices, cosmetics, food supplements and even biocides. She is working hand-in-hand with Vivactis HM3A.
Olivier Ethgen, PhD – Senior Health Economist
Olivier is Associate Professor of Health Economics at the Department of Public Health Sciences, Faculty of Medicine, University of Liège in Belgium. He is also an invited lecturer at the Department of Pharmacy and the Department of Biomedical Sciences, Faculty of Medicine, University of Namur in Belgium. He lectures in health economics (theory & applied modeling), decision sciences and pharmacoepidemiology. Olivier holds a PhD in Public Health Sciences from the University de Liège and an MSc in Mathematical Economics from the University of Paris I – Panthéon Sorbonne. His research interests include financial modeling of patients and market access strategies and population-based modeling. Olivier has nearly 20 years of experience as an economic and financial modeler gained in the private sector at IMS Health (now IQVIA), Bristol-Myers & Squibb and GlaxoSmithKline Vaccines. Olivier has designed numerous economic and financial models across a broad spectrum of disease areas and his experience spans all types of healthcare technologies including drugs, biologics, vaccines, devices, and diagnostics.
Mark Nuijten, MD, PhD – Senior Health Economist
Mark Nuijten is medical doctor, health economist, market access and pricing consultant, valuation economist, and healthcare policy journalist. Mark Nuijten has a varied career in the health academic and business environment. He is pursuing development of economic modelling and broadening its application in health care and finance. His reimbursement dossiers, incl. cost-effectiveness and BIA models, successfully contributed to positive reimbursement decisions by health authorities in many countries, (for example, NICE in England, SMC in Scotland, TLV in Sweden, CADTH in Canada, Zin in The Netherlands, RIZIV/INMAI in Belgium).
He is academic supervisor of PhD programs at the Universities of Maastricht and Groningen in The Netherlands and founder of the ISPOR Special Interest Group on nutrition-economics. Since 2017 he is Adjunct Professor at ITU (Istanbul Technical University) in International Healthcare Assessment and Valuation.
Will Toenders, PharmD – Market Access Consultant
Wil Toenders was trained as a pharmacist and, in his minor in general practice, has conducted research into the prescribing behavior of general practitioners. After working as a practice pharmacist for some years, he specialized in pharmacotherapy. He was, among other things, editor-in-chief of the Dutch Drug Bulletin and editor of the Pharmacotherapeutic Compass. His last governmental job was as head of drug assessment at the National Health Care Institute, responsible for the advices to the Ministry of Health about the therapeuitic value, budgetimpact and cost-effectiveness of all new medicines. For more than thirteen years he has gained experience as an independent consultant in the field of the reimbursement of medicines, as of 1 January 2023 from Advamedic.
Géraldine Materne, DVM – Market Access Consultant
Géraldine is Doctor of Veterinary Medecine. She also holds a MSc in Public Health Sciences with a major in Epidemiology and Health economics. She is currently following the Master in Medicine (University of Liege). She brings expertise in infectious diseases and antibiotics. Moreover, she is passionate about internal medicine and patient care. She joined Vivactis HM3A in July 2022.
Chris Juliam, MD, MBA – Market Access Consultant
Christine Juliam started her career in clinical research at MSD in Belgium before moving into product management, and subsequently into sales, marketing, and business planning responsibilities. In July 1996, she started to work for Abbott Belgium as director of the pharmaceutical product division, and joined Nycomed as managing director Belgium/Luxembourg in 2006. From 2011 onwards, she was region head for France, the Netherlands, Belgium, and Luxembourg for Nycomed, which was acquired by Takeda in the same year. Subsequently, Ms. Juliam managed Takeda Italy and France as country manager between 2013 and 2017. In 2021-2022, she was general manager at Orifarm. Christine Juliam has a Doctor’s Degree of Medicine from the University of Ghent, a License in Marketing from St. Aloysius College in Brussels, a Master in Management from Solvay Commercial School in Brussels, and an MBA from Northwestern University.
Vivactis Weber – The Spanish Team
Click here to learn more about our team located in Spain.
Vivactis Weber has a leading position in Spain for global pharma, biotech, and medical device companies with a primary expertise in several therapeutic areas, including rare disease and oncology. With its team of more than 25 highly qualified employees Weber owns more than 15 years of experience and carried out more than 230 projects. The company has an impressive track record in Health Outcome Research including Social Return On Investment (SROI) projects, a type of economic evaluation with the possibility of involving patients. Weber is also a leader in Multicriteria Decision Analysis (MCDA) projects, a structured process that offers greater flexibility to incorporate multiple objectives in comparison to cost-effectiveness analysis or cost-utility analysis. In addition, Weber Foundation allows leading projects in collaboration with patient associations and public entities in order to improve the patients engagement process.
THIBAULT COLIN – Consultant
Thibault Colin started his career as an economic analyst specializing in the macroeconomic approach to business and government relations in both France and Europe. He then moved on to social protection and life insurance and then to public affairs and market access consulting for healthcare products. He holds an MSc in Economics from Sciences Po Bordeaux and is studying public health at the Paris School of Medicine. Driven by health issues and knowledgeable of regulatory, political, social and financial obligations and opportunities, he brings his expertise in healthcare systems, health democracy and patient value. Thibault joined Vivactis in December 2022.